# EDGAR Filing Document

**Accession Number:** 0001042418
**File Stem:** 0000000000-25-007569
**Filing Date:** 2025-7
**Character Count:** 3205
**Document Hash:** c774f42a6a1710a2943fe6519735c252
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007569.hdr.sgml**: 20260122

**ACCESSION NUMBER**: 0000000000-25-007569

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250717

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibitor Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042418
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 541641133
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-13467

**BUSINESS ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609
- **BUSINESS PHONE:** (813) 766-2462

**MAIL ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HedgePath Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMONWEALTH BIOTECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19970714
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-001190

## Text-Extract

```

                                                           July 17, 2025

James A. McNulty
Interim Chief Financial Officer
Inhibitor Therapeutics, Inc.
3014 W. Palmira Avenue
Suite 302
Tampa, FL 33629

        Re: Inhibitor Therapeutics, Inc.
            Form 10-K for the Year Ended December 31, 2024
            Filed March 28, 2025
            File No. 001-13467
Dear James A. McNulty:

       We have reviewed your filing and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe
this comment applies to your facts and circumstances, please tell us why in
your response.

       After reviewing your response to this letter, we may have additional
comments.

Annual Report on Form 10-K
Item 1. Description of Business, page 3

1.     We note your disclosure on page 3 that, on December 12, 2023, you
entered into an
       Exclusive License Agreement with Johns Hopkins University. In future
filings, please
       provide further details about the material terms of this agreement
including, but not
       limited to, the aggregate amount that could be owed to Johns Hopkins
University
       pursuant to the agreement, the aggregate milestone amounts to be paid,
and the
       royalty range and term, as applicable.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Joshua Gorsky at 202-551-7836 or Chris Edwards at
202-551-6761 if
you have questions regarding the comment.
 July 17, 2025
Page 2

                Sincerely,

                Division of Corporation Finance
                Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._